| Metric | Value ($ M) | Q1 FY26 | Q2 FY25 |
|---|---|---|---|
| Revenue | 0.51 | 27.1% | 90.4% |
| Total Income | 0.51 | 27.1% | 90.4% |
| Expenditure | 97.89 | 11.3% | 44.9% |
| PBT | -94.47 | 59.2% | |
| Net Profit | -94.47 | 11.4% | 59.0% |
| OPM | — | ||
| NPM | — | ||
| EPS | -1.09 | 10.1% | 28.2% |
EyePoint Reports Q2 2026 Financial Results and Highlights Recent Corporate Developments
05 Aug 2026 · 5 Aug, 4:37 pm
Summary
EyePoint, Inc. announced its financial results for the second quarter ended June 30, 2026, reporting total net revenue of $0.5 million, a decrease from $5.3 million in the prior year period, attributed to deferred revenue recognition. Operating expenses increased to $97.9 million from $67.6 million, driven by clinical trial advancements and manufacturing scale-up, resulting in a net loss of $94.5 million, or ($1.09) per share. The company ended the quarter with $180 million in cash and investments, sufficient to fund operations into Q4 2027. Key clinical development milestones are approaching, with topline data for the LUGANO wet AMD trial expected in August 2026 and for the LUCIA trial in Q4 2026, while enrollment is complete for the DME trials with data expected in Q4 2027.
Key Highlights
- 1
EyePoint reported total net revenue of $0.5 million for the second quarter ended June 30, 2026, a decrease compared to $5.3 million for the corresponding period in 2025, primarily due to deferred revenue recognition.
- 2
Operating expenses for Q2 2026 totaled $97.9 million, an increase from $67.6 million in Q2 2025, driven by ongoing DURAVYU Phase 3 clinical trials and commercial manufacturing scale-up.
- 3
The company reported a net loss of $94.5 million, or ($1.09) per share, for the second quarter of 2026, compared to a net loss of $59.4 million, or ($0.85) per share, in the prior year period.
- 4
As of June 30, 2026, EyePoint had $180 million in cash and investments, providing an operational runway into the fourth quarter of 2027.
- 5
Topline data from the LUGANO pivotal Phase 3 wet AMD clinical trial is expected in August 2026, followed by LUCIA data in Q4 2026.
- 6
Enrollment for the pivotal Phase 3 DME clinical trials, COMO and CAPRI, is complete, with topline data anticipated in Q4 2027.
Management Comments
Jay S. Duker
M.D.
With topline data from our pivotal Phase 3 LUGANO wet AMD trial expected this month, followed by LUCIA in the fourth quarter, and enrollment now completed in our pivotal Phase 3 DME program, we continue to execute across our clinical programs. The LUGANO and LUCIA data readouts represent transformative advancement in the wet AMD landscape, potentially positioning DURAVYU as the foundational treatment option for sustained patient care.
Informational and educational content only. Not investment advice.